Therapeutic strategies targeting BRG1‐dependent pathways (ABCC3 inhibition, MALAT1 silencing, or GLMP/PI3K‐AKT modulation) demonstrate preclinical efficacy, validating its role as an actionable node in HCC pathogenesis [73, 76, 77]. Here, SMARCA4 is linked to hepatocellular carcinoma.